A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes Mellitus

Trial Profile

A Phase IIb, Randomised, Parallel, Double-Blind Placebo-Controlled and Open-Label Active Comparator Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes Mellitus

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 21 May 2018

At a glance

  • Drugs MEDI 0382 (Primary) ; Liraglutide; Metformin
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 23 Apr 2018 Planned End Date changed from 23 Mar 2020 to 5 Mar 2020.
    • 22 Jan 2018 Status changed from recruiting to active, no longer recruiting.
    • 20 Dec 2017 Planned End Date changed from 27 Apr 2020 to 23 Mar 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top